Sign In
Buy CRSP
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026
CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)
04:07pm, Tuesday, 03'rd Jun 2025
CRISPR Therapeutics AG (NASDAQ:CRSP ) William Blair's 45th Annual Growth Stock Conference June 3, 2025 12:20 PM ET Company Participants Raju Prasad - Chief Financial Officer Conference Call Participan
The Best Stocks to Invest $1,000 in Right Now
04:30am, Tuesday, 03'rd Jun 2025
Are you just as afraid of a market pullback right now as you are of missing out on upside? If so, you're not alone.
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
08:30am, Thursday, 29'th May 2025
ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseas
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
10:06am, Monday, 26'th May 2025
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
12:51pm, Tuesday, 20'th May 2025
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
5 Monster Stocks to Hold for the Next 10 Years
04:30am, Tuesday, 20'th May 2025
The professionals who manage Wall Street funds and cater to wealthy investors live and die by their quarterly performance. However, the individual investor can win the long game by focusing on what wi
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?
03:43am, Tuesday, 20'th May 2025
Shares of gene therapy specialist, CRISPR Therapeutics (CRSP -0.34%) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first tre
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
09:30am, Sunday, 18'th May 2025
Despite making significant clinical progress, CRISPR Therapeutics (CRSP 6.83%) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while the
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
07:15am, Friday, 16'th May 2025
Ever since scientists began mapping the human genome, gene editing has always been the end goal. The idea once seemed like something out of a science fiction novel, but it's here today and CRSPR Ther
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Tuesday, 13'th May 2025
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
2 Biotech Stocks That Are Screaming Buys in May
07:10am, Tuesday, 13'th May 2025
It's very tempting to pile into the stocks with the strongest positive momentum of the moment -- they've proven themselves and could continue along this path. But in many cases, you could set yourself
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?
06:18am, Monday, 12'th May 2025
Our genetics are like nature's roadmap. Our DNA dictates what color eyes we have, how tall we become, and our physical abilities.
3 Monster Stocks to Hold for the Next 10 Years
05:12am, Saturday, 10'th May 2025
The best investments are often stocks of companies offering goods and services that are perpetually in demand. Think entertainment, healthcare, or more recently, some consumer technologies.
Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines
07:14am, Friday, 09'th May 2025
CRSP's main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It's a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy's rollout has been s
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:22am, Thursday, 08'th May 2025
Growth stocks have been rallying in recent weeks, and that's usually great news for Cathie Wood. The founder, CEO, and stock-picking ace of the Ark Invest family of exchange-traded funds (ETFs) has mo
